The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 21, 2025
Filed:
Nov. 27, 2019
Guangzhou Liushun Biotechnology Co., Ltd., Guangdong, CN;
Beijing Beikehuaxia Bio-medical Technology Co., Ltd., Beijing, CN;
Bing Liu, Guangdong, CN;
Jingsi Dai, Guangdong, CN;
Yan Wang, Beijing, CN;
Xueqi Qian, Guangdong, CN;
Junjun Dong, Beijing, CN;
Xihong Liu, Guangdong, CN;
Lianwu Deng, Guangdong, CN;
Shuang Xie, Guangdong, CN;
Daping Li, Guangdong, CN;
Nengan Chen, Guangdong, CN;
Jin Ma, Guangdong, CN;
GUANGZHOU LIUSHUN BIOTECHNOLOGY CO., LTD., Guangdong, CN;
BEIJING BEIKEHUAXIA BIO-MEDICAL TECHNOLOGY CO., LTD., Beijing, CN;
Abstract
A multi-target kinase inhibitor is shown in formula (I), in which R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit the enzymatic activities of RET, VEGFR3 and PDGFRA, and can effectively treat diseases that are regulated and controlled by multi-target kinases and are related to abnormal signal transduction pathways of the multi-target kinases, including cancers of breast, respiratory tract, brain, reproductive organ, digestive tract, urinary tract, eye, liver, skin, head and/or neck and distant metastatic cancers thereof, and lymphoma, sarcoma, leukemia and the like. The active ingredients of the pharmaceutical composition of the present invention comprise a multi-target kinase inhibitor, which accounts for 1-50 wt % of the composition.